• Parkinsonism

Inbrija Generic Name & Formulations

General Description

Levodopa 42mg; per cap; dry pwd for oral inh.

Pharmacological Class

Dopamine precursor.

How Supplied

Caps (w. inhaler)—60, 92


Generic Availability


Inbrija Indications


Intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.

Inbrija Dosage and Administration


For oral inh only; use with Inbrija inhaler. Do not swallow caps. Inhale contents of 2 caps (84mg) as needed, up to 5 times daily. Max dose per OFF period: 84mg; max daily dose: 420mg.


Not established.

Inbrija Contraindications


During or within 14 days of nonselective MAOIs (eg, phenelzine, tranylcypromine).

Inbrija Boxed Warnings

Not Applicable

Inbrija Warnings/Precautions


Sleep disorders: consider discontinuing if significant daytime sleepiness occurs. Withdrawal-emergent hyperpyrexia or confusion: avoid rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Increased risk of hallucinations and psychosis. Major psychotic disorder, asthma, COPD, chronic lung disease: not recommended. Impulse control disorders: consider discontinuing if occurs. Glaucoma: monitor IOP. Pregnancy. Nursing mothers.

Inbrija Pharmacokinetics

See Literature

Inbrija Interactions


See Contraindications. Orthostatic hypotension with MAO-B inhibitors; monitor. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts; monitor. May cause false (+) plasma/urine results suggesting pheochromocytoma.

Inbrija Adverse Reactions

Adverse Reactions

Cough, nausea, upper respiratory tract infection, sputum discolored; dyskinesia (adjust doses), CNS disturbances (eg, hallucinations, confusion, somnolence), bronchospasm, increased IOP, lab abnormalities.

Inbrija Clinical Trials

See Literature

Inbrija Note

Not Applicable

Inbrija Patient Counseling

See Literature